BridgeMD
New treatment option for Moderate to Severe Chronic Obstructive Pulmonary Disease
Official title A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov ID: NCT07363694
What this study is testing
What is PF-07275315 dose 1?
PF-07275315 dose 1 is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for moderate to severe chronic obstructive pulmonary disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.
- Phase 3: a large, late-stage study
- Time commitment: about 68 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 80
You may be able to join if
- Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease...
- Spirometry values (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] less than [\<] 70 percent (%) and...
- Continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3...
- Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening. Key
You likely can't join if
- Significant pulmonary disease other than COPD.
- Requirement for continuous chronic treatment with oxygen at \>4.0 liters / minute by nasal cannula or equivalent.
- Hypoxemia with a resting SpO2 \<88% while breathing ambient air (or on the participant's usual level of oxygen supplementation).
- Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor...
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Dothan, Alabama, United States
- Mobile, Alabama, United States
- Chandler, Arizona, United States
- Phoenix, Arizona, United States
- La Palma, California, United States
- Newport Beach, California, United States
- Northridge, California, United States
- San Diego, California, United States
- Greenacres City, Florida, United States
- Kissimmee, Florida, United States
- Loxahatchee Groves, Florida, United States
- Miami, Florida, United States
- Ocala, Florida, United States
- St. Petersburg, Florida, United States
- Winter Park, Florida, United States
- East Point, Georgia, United States
- Rincon, Georgia, United States
- Hammond, Indiana, United States
- Merrillville, Indiana, United States
+ 56 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 68 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 35 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Dothan, Alabama, United States; Mobile, Alabama, United States; Chandler, Arizona, United States; Phoenix, Arizona, United States; La Palma, California, United States and 70 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.